We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

58 hedge funds and large institutions have $110M invested in Xenon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

1.22% less ownership

Funds ownership: 70.37% → 69.15% (-1.2%)

2% less funds holding

Funds holding: 59 → 58 (-1)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

53% less capital invested

Capital invested by funds: $234M → $110M (-$124M)

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
12
Increased
23
Reduced
6
Closed
12
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$5.54M
2
ACM
Aquilo Capital Management
California
+$3.19M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.89M
4
BlackRock
BlackRock
New York
+$2.52M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.61M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$11.8M
2
OM
Opaleye Management
Massachusetts
-$7.01M
3
FCMI
Foresite Capital Management IV
California
-$5.09M
4
JG
Jefferies Group
New York
-$4.3M
5
BC
Boxer Capital
California
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$15.1M +$291K +32,782 +1%
BI
2
BVF Inc
California
$11.3M +$5.54M +623,221 +53%
VC
3
Vivo Capital
California
$8.87M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$8.2M +$889K +100,000 +8%
Capital World Investors
5
Capital World Investors
California
$6.08M – – –
ACM
6
Aquilo Capital Management
California
$6M +$3.19M +358,725 +61%
Capital International Investors
7
Capital International Investors
California
$5.92M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$5.29M +$750K +84,367 +11%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$4.58M +$2.89M +325,000 +81%
O
10
OrbiMed
New York
$4.01M – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$3.57M +$341K +38,363 +7%
ACP
12
Acuta Capital Partners
California
$3.39M +$489K +55,000 +11%
SSA
13
Schonfeld Strategic Advisors
New York
$3.09M -$643K -72,355 -13%
SFM
14
Sphera Funds Management
Israel
$2.84M +$622K +70,000 +18%
EAM
15
Eventide Asset Management
Massachusetts
$2.68M +$973K +109,433 +35%
BlackRock
16
BlackRock
New York
$1.79M +$2.52M +283,708 New
GPCM
17
Granite Point Capital Management
Massachusetts
$1.6M -$1.88M -211,000 -45%
DCM
18
DAFNA Capital Management
California
$1.5M – – –
EP
19
Eversept Partners
New York
$1.29M -$41.2K -4,635 -2%
Two Sigma Investments
20
Two Sigma Investments
New York
$1.26M +$1.1M +123,676 +161%
JP Morgan Chase
21
JP Morgan Chase
New York
$1.2M +$1.61M +181,381 +2,152%
DMK
22
David M. Knott
$1.09M – – –
State of New Jersey Common Pension Fund D
23
State of New Jersey Common Pension Fund D
New Jersey
$979K – – –
AGA
24
Altrinsic Global Advisors
Connecticut
$947K +$267K +30,000 +25%
Millennium Management
25
Millennium Management
New York
$917K +$556K +62,509 +75%
1
2 3

XENE Hedge Fund Activity: Q4 2018 in Review

58 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2018, worth a combined $110M — down 53% from $234M a quarter earlier.

Fund positioning in XENE was balanced in Q4 2018: 12 funds opened new positions, 12 closed out, 23 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $5.54M. The largest seller was Broadfin Capital, exiting entirely with an estimated $11.8M sold.

  • 58 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2018, down from 59 in Q3 2018.
  • Funds reported $110M of Xenon Pharmaceuticals stock for Q4 2018, down 53% quarter-over-quarter.
  • 12 funds opened new Xenon Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of 0 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2018 was BVF Inc, an estimated $5.54M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2018 was Broadfin Capital, an estimated $11.8M sold.

Based on aggregated 13F filings for Q4 2018.